The sheer magnitude of the ATM authorization relative to market cap (nearly 1x market cap at ~$1.55) is an intensely bearish signal for a pre-revenue biotech with a partial clinical hold. Expect heavy downward pressure on PEPG as the market prices in substantial future dilution. Monitor daily volume on Nasdaq — if the ATM is actively used, share price will likely drift lower toward cash-adjusted values. The unresolved FDA hold adds binary risk but the dilution overhang is the dominant near-term factor.
Price Chart
Executive Summary
PepGen filed a new universal shelf registration statement (S-3) for up to $400M in securities, including a $100M ATM facility with Stifel that replaces a prior ATM with $88.5M remaining capacity. The filing comes 7 days after the company reported a Q1 2026 net loss of $17.8M and cash of $132.3M (sufficient into 2H 2027), with an unresolved FDA partial clinical hold on its lead DM1 candidate. The massive increase in authorized ATM capacity ($88.5M remaining → $100M new + $300M other shelf) signals management's expectation of needing significant capital beyond current runway to fund operations through clinical milestones, creating material dilution risk for existing shareholders.
Key Financial Metrics
Key Facts
- New S-3 shelf registration for up to $400M in securities, including a $100M ATM facility with Stifel
- ATM replaces prior $100M facility (August 2023) under which $88.5M remained unsold
- Q1 2026 net loss of $17.8M ($-0.26/share), cash and marketable securities of $132.3M
- Cash runway sufficient into 2H 2027 per prior earnings disclosure
- Unresolved FDA partial clinical hold on PGN-EDODM1 for DM1
- Closing price of $1.55/share on May 15, 2026; market cap ~$107M based on 69.2M shares outstanding
- Pro forma outstanding shares at $1.55 would be up to ~133.7M if full $100M ATM sold, representing ~93% dilution
Financial Impact
Up to $100M in potential ATM sales at ~$1.55/share would dilute existing shareholders by ~93% (69.2M to 133.7M shares outstanding). Cash runway extended into 2H 2027 but at massive cost to current holders.
Risk Factors
- Dilution from ATM sales could exceed 90% if the full $100M facility is utilized
- Unresolved FDA partial clinical hold on lead candidate PGN-EDODM1 creates regulatory overhang
- Cash runway only into 2H 2027 — the shelf signals management expects to need capital beyond that
- Pre-revenue clinical-stage biotech with no approved products and ongoing operating losses
- Stock price near all-time lows with limited downside protection against continued ATM selling
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-228960 |
| Document: d132482dex12.htm | 0001193125-26-228960 |
| Document: d132482dexfilingfees.htm | 0001193125-26-228960 |
| Document: d132482dex51.htm | 0001193125-26-228960 |
| Document: d132482dex52.htm | 0001193125-26-228960 |
| Document: d132482dex231.htm | 0001193125-26-228960 |
| Document: 0001193125-26-228960-index-headers.html | 0001193125-26-228960 |
| Document: 0001193125-26-228960-index.html | 0001193125-26-228960 |
| Document: 0001193125-26-228960.txt | 0001193125-26-228960 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $2.41 $3.18 | ▲ +31.95% | ▲ +31.35% | $2.28 (−5.60%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.51 $2.30 | ▲ +52.32% | ▲ +50.43% | $2.28 (+50.66%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.51 $2.30 | ▲ +52.32% | ▲ +50.43% | $2.28 (+50.66%) |
May 22, 2026 19w ago | EFFECT | $1.51 $1.90 | ▼ −25.83% | ▼ −27.24% | $2.28 (−50.66%) |
May 19, 2026 19w ago | S-3 | $1.38 $1.70 | ▼ −23.19% | ▼ −22.20% | $2.28 (−64.86%) |
May 12, 2026 20w ago | 8-K | $1.78 $1.51 | ▼ −15.17% | ▼ −14.56% | $2.28 (+27.81%) |
Mar 4, 2026 30w ago | 8-K | $5.51 $1.73 | ▼ −68.57% | ▼ −64.79% | $2.28 (−58.67%) |
Mar 4, 2026 30w ago | Insider Cluster | $6.76 $1.74 | ▼ −74.26% | ▼ −69.84% | $2.28 (−66.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access